Descargar

Tratamientos empleados en el control de la fasciola hepática (página 2)

Partes: 1, 2

  • 7. Boray JC, Sluyter V, Cambell NJ, McKinnon A. Resistance of inmature and adult Fasciola hepatica to Triclabendazole in the field. In proceedings of the 16 th International conference of the WAAVP. 1997: 10.

  • 8. Boray JC, Sluyter V. Efficacy of a closantel / oxfendazole combination against Fasciola hepatica in sheep. In proceeding of the 16th International Conference of the WAAVP. Sun city. 1997: 10.

  • 9. Boray JC. Chemotherapy of infections with Fasciolidac. In Immunology Pathobiology and control of fasciolosis. Ed. J.C. 1997: 83-97. Rahway, New Jersey: MSD AGVET.

  • 10. Boray, J.C. Drug resistance in Fasciola hepatica. IN resistence of Parasites to Antiparasitic Drugs, ed. J.C.1993

  • 11. Boray, P.J. Martin & R.T. Roush, 1990 pp. 51-60. Rahway, New Jersy: MSD AGVET.

  • 12. Boray,J.C . The present status of anthielmintic resistance in Fasciola hepatica. In Proceedings of the 14th International Conference of the WAAVP,(1993b)

  • 13. Brewer MD, Dorgan RJ, Manger BR, Mamalis P, Webster RA. Isothiourea derivatives of 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole with broad-spectrum anthelmintic activity. J Med Chem 1987; 30: 1848-53.

  • 14. Cambell AJ, Montague PE. A comparison of the activity of uncouplers of oxidative phosphorilation against the common liver fluke Fasciola hepatica. Parasitol 1981; 4: 139-47.

  • 15. Cerrud NI, Quiroz H. Valoración de huevos de Fasciola hepatica en heces de ovinos tratados con closantel y nitroxinil. Vet Méx 1995;26:151-54.

  • 16. Charbon JL, Spahai M, Wicki P, Fister P. Cellular reactions in the small infection of rats after firation with Fasciola hepatica laboratory of parasitology. Parasitol-pes 1991; 77: 425-29.

  • 17. Chen MG, Mott KE. Progress in assessment of morbidity due to Fasciola hepatica. infection. Trop Dis Bull 97. RI-R37. 1990.

  • 18. Coles GC. Anthelmintic activity of Triclabendazole. J. Helminthol. 1986; 60: 210-12.

  • 19. Conder GA, Kuo Ming-Shang, Marshall VP, Zielinski RJ. Dioxapyrrolomycin as an antiparasitic agent and compositions useful therefore. United States Patent Number 563940. 1997.

  • 20. Corba J, Velebny S. And Spaldonova R: Primary screening of newly synthetized substances in white mice invaded with Fasciola hepatica. Helminthologia 1981; 18: 43-52.

  • 21. Cornelissen JB, Gaasenbeek CP, Boersma W, Borgsteede FH, Milligen J. Use of a pre-selected epitopeof cathepsin-L1 in higly specific peptide-based immunoassay for the diagnosis of Fasciola hepatica infections in cattle. Int J Parasitol 1999; 29: 685-96.

  • 22. Cruz R, Pérez A, Rodríguez S. Valoración in vitro de la bioactividad del G-1 sobre la vitalidad de la Fasciola hepatica. III Seminario Científico CENSA, La Habana. Resúmenes p. 157. 1983.

  • 23. Dawes B. Maintenance in vitro of Fasciola hepatica. Nature (Lond ) 1954;174:654- 655.

  • 24. Díaz W. Valoración de la efectividad de diferentes sustancias bioactivas contra la Fasciola hepatica. Trabajo de Diploma presentado para obtener el título de Doctor en Medicina Veterinaria en la Facultad de Ciencias Agropecuarias de la Universidad Central Marta Abreu de Las Villas. Santa Clara, Villa Clara, 1991.

  • 25. Dixon KE. The structure and histochemistry of the cyst wall of the metacercaria of Fasciola hepatica L. Parasitol 1965; 55: 215-26.

  • 26. Dowd AJ, Smith AM, McGonigle S. and Dalton J. Purification an characterization of a second Capthesin L protease secreted by the parasitic trematode Fasciola hepatica . Eur J Biochem 1994; 223: 91-98.

  • 27. Eckert J, Scheiter G, Wolf K. Fasinex (Triclabendazole) ein neues Fasciolizid. Berl Münch Tierärztl Wochensch 1984;97;349-356.

  • 28. Espaine L, Lines R, Demedio J. Manual de Parasitología y enfermedades Parasitarias I. Editorial MES. Habana. P. 103. 1996.

  • 29. Estrada E, Gómez M, Castañedo N, Pérez C. Theoretical and experimental study on the structure of 1-(5-X-fur-2-yl)-2-nitro-2-Y-ethylenes. J Moll Struct (THEOCHEM) 1999;468:193-200.

  • 30. Estuningsih E, Smooker PM, Wiedosari E, Widjajanti S, Vaiano S, Partoutomo S, Spithill TW. Evaluation of antigens of Fasciola gigantica as vaccines against tropical fasciolosis in cattle. Int J Parasitol 1997; 27: 1419-28.

  • 31. Fabiyi JP. Production losses and control of helminths in ruminanst of tropical region.

    • Int J Parasitol 1987; 17: 435-42.

    • 32. Fairweather I y McDowell LSL. Clorsulon action: Just skin deep or a real " blood and guts " performance? Proceeding of the Royal Microscopical Society. 1995; 30: 1.

    • 33. Fairweather I, Anderson HR, Threadgold LT. Fasciola hepatica morphological changes in viteline cells following treatment in vitro with the diacetilated (amine) metabolite of diamphenethide (DAMD). Int J Parasitol 1988; 18: 1061-9.

    • 34. Fairweather I, Boray C. Mechanism of fasciolicide action and drug resistance in Fasciola hepatica. In Fasciolosis edited by JP Dalton Dublin city University Republic of Ireland. 1998.

    • 35. Fairweather I, Boray C. Fasciolicides: Efficacy. Actions, resistance and its management. Vet J 1999; 158: 81-112.

    • 36. Fairweather I, Holmes SD, Threadgold LT. Fasciola hepatica: motility response to fasciolicides in vitro . Expl Parasitol 1984; 57: 209- 24.

    • 37. Fairweather I, Holmes SD. and Threadgold LT. Fasciola hepatica: a technique for monitoring in vitro motility. Exp Parasitol 1983; 56: 369-80.

    • 38. Fairweather I. The quest for an understanding of fasciolicida action: Holy Grail or poisoned chalice?. In Immunology, Pathology and control of Fasciolosis. Ed. J.C. Boray, Rahway, New Jersey: MSD AGVET. 1997: 91-130.

    • 39. Goldin A, Benedith JM,Carter SK Screening at the National Cancer Institute. National Cancer Institute. Monograph 45. 1955.

    • 40. González AR. Evaluación in vitro e in vivo de productos sintéticos de la serie G sobre Fasciola hepatica. Trabajo de Diploma presentado para obtener el título de Licenciada en Farmacia en la Facultad de Química y Farmacia de la Universidad Central Marta Abreu de las Villas. Santa Clara, Villa Clara, 2000.

    • 41. Hairfenist M. Diamfenetide a new fasciolicide active against parasite. Pesticide Science. 1973; 4: 871-72.

    • 42. Happich FA, Boray JC. Cuantitative diagnosis of chronic fasciolosis.1. Comparative studies on quantitative faecal examinations for chronic Fasciola hepatica infection in sheep. Aust Vet J 1969a ;45:326-28.

    • 43. Happich FA, Boray JC. Cuantitative diagnosis of chronic fasciolosis. 2. The estmation of daily total egg production of Fasciola hepatica and the number of adult flukes in sheep by faecal egg counts. Aust Vet J 1969b ;45:329-31.

    • 44. Hawkins CD, Morris RS. Depression of productivity in sheep infected with Fasciola hepatica. Vet Parasitol 1974;4:341-51.

    • 45. Hawkins CD. Productivity in sheep treated with diamphenetide at different times after infection with Fasciola hepatica . Vet Parasitol 1984;15:117-123.

    • 46. Hayes TJ, Bailer J, Mitrovic M. Murine fascioliasis: Laboratory model for the detection of fasciolicidal activity of chemical compounds. J Parasitol 1973b;59:314- 18.

    • 47. Hayes TJ, Bailer J, Mitrovic M. The chemotherapeutic activity of selected fasciolicides against immature Fasciola hepatica in mice. Experientia 1973c;29:899-900.

    • 48. Hayes TJ, Bailer J, Mitrovic M. The pattern of mortality in mice experimentally infected with Fasciola hepatica. Int J Parasitol 1973a;3:665-69.

    • 49. Hayes TJ, Mitrovic M. The fasciolicidal activity of a halogenated benzenesulfonanilide. Experientia. 1979; 35: 325-26.

    • 50. Hilario A , Cordovés C, García J, Tamayo S, Leiva A, López JM. Evaluación de los formulados UC-244 y G-1 al 10% como fasciolicidas. Informe Técnico del CENSA. 1992.

    • 51. Hillyer GV, Apt W. "Food-born trematode infections in the Americas". Parasitology Today .1997; 13: 87-88.

    • 52. Hoban DJ. G-1 mecanism of action study. Manitoba University. 1998a:1- 30.

    • 53. Hoban DJ. G-1 mecanismo of action study. Manitoba University. 1998b: 30.

    • 54. Jackson F. Anthelmintic resistance the state play. Brit Vet J 1993; 149: 123-38.

    • 55. Jaffe JJ, Doremus HM, Meymarian E. The activity of tuberciding against the

    hepatica Fasciola inmature in mouse. J Parasitol 1976; 62: 910-13.

    • 56. Knox DP, Redmond DL, Skuce PJ, Newlands GF. The contribution of molecular biology to the development of vaccines against nematode and trematode parasites of domestic ruminants. Vet Parasitol 2001;101:311-35.

    • 57. Knox DP. Parasite enzymes and the control of roundworm and fluke infestation in domestic animals. Br Vet J 1994;150:319-337.

    • 58. Lapage G. Parasitología veterinaria. 1975: 235-40.

    • 59. Lloyd GM, Barrett J. Fasciola hepatica carbohydrate metabolism of the adult.

    Expl Parasitol 1983; 56: 81-88.

    • 60. Malone JB, Loyacano AF, HUGH-Jones ME and Corkum. A. Threeyear study on seasonal transmission and control of Fasciola hepática of cattle in Lousiana.Prev Vet Med 1984., 3: 131-141.

    • 61. Malone JB. The landscape Epidemiology of faciolosis: Geographic determinants of disease risk. In immunology; Pathobiology and control of faciolosis, ed. Boray JC. Rahway, New Jersey: MSD AGVET. 1997: 61-85.

    • 62. Manssoud J. Fascioliasis outbreak of man and drug test (triclabendazole) in Caspian littoral, northern part of Iran, In proceeding of the 7th International Congress of Parasitology, Paris, 9910.Bulletin de la société Francaise de parasitologie B. 1990. (Suppl.1), 438.

    • 63. Marcet R, Diaz A, Arteaga E, Finlay CM, Sarracent J. Passive protection against fasciolosis in mice by immunization with a monoclonal antibody (ES- 78 MoAb). Parasite Immunol 2002;24:103-8.

    • 64. Martin RJ. Modes of action of anthelmintic drugs. Vet J 1997; 154: 11-34.

    • 65. Mc Kellar QA, Kinabo LDB. The Pharmacology of flukicidal drugs. Br Vet J

    1991;147:306-21.

    • 66. Milligen FJ, Cornelissen JB, Guasenbeek CP. and Bokhout BA. A novel ex vivo rat infection model to study protective immunity against Fasciola hepatica at the gut level. J immunol met 213 1998: 183-90.

    • 67. Mitterpak J, Mendéz M, Mauri M. Problemas relacionados con los hospederos intermediarios de Fasciola hepatica en Cuba. Serie biológica. 1972; 30: 1-24.

    • 68. Mol y Biochem Coles GC. Anthelmiintic activity of Triclabendazole. Journal of Helminthology 2000; 60: 210-212.

    • 69. Moll A, Gaasenbeek CPH, Vellema P, Borgsteede FHM. Resistance of Fasciola hepatica against triclabendazole in cattle and sheep in the Netherland. Vet Parasitol 2000;91:153-58.

    • 70. More A, Castillo N, Borges M, Fernández N, Osorio M. Fascioliasis humana: Manifestaciones clínicas y diagnostico en pacientes en el municipio de Santa Clara. 1994. Xlll Congreso Latinoamericano de Parasitología. La Habana, Cuba. 1997: 126.

    • 71. Morrilla A, Bautista CR. Manual de Inmonulogía. Editorial Diana, México. P. 41. 1987.

    • 72. Novoa H, Pomés R, Duque J, Toscano RA. Crystal structure of 5-bromo-2-(2-bromo- 2-nitroethenyl) furan, C6H3Br2NO3. Zeitschrift für Kristallographie 1996;211.

    • 73. Núñez MT, Quiroz H. Efecto de tratamientos sistemáticos con Nitroxinil en la

    reducción de huevos de Fasciola hepátca en ganado de Lidia. Vet Méx

    1994;25:341-43.

    • 74. O´Neill S, Parkinson M, Strauss W. Inmunodiagnosis of Fasciola hepatica infection (fascioliasis) in a human population in the Bolivian Altiplano using purified cathepsin L cysteine proteinase. American Journal of Tropical Medicine and Hygiene 1998; 58: 417-28.

    • 75. Olazábal E, Morales A, Serrano H, Brito E. Obtención de metacercarias de Fasciola hepatica en Lymnaea cubensis y relación parásito – hospedero en ratas Wistar y ratones Balb/c. Vet. Méx 1999; 30: 109-14.

    • 76. OPS. El Control de las Enfermedades Transmisibles en el Hombre. Ed. 1985.

    • 77. Overend DJ, Bowen FL. Resistance of Fasciola hepatica to triclabendazole. Aust Vet J 1995; 72: 275-76.

    • 78. Parr SL, Gray JS. A strategic dosing scheme forthe control of fasciolosis in cattle and shep in Ireland. Vet Parasitol 2000;88:3-4:187-197.

    • 79. Paz-SilvaA, Pedreira J, Sanchez-Andrade R, Suarez JL, Diaz P, Panadero R, Diez-BanosP, MorrondoP.Time-course analysis of coproantigens in rats infected and challenged with Fasciola hepatica. Parasitol Res 2002;88:568- 73.

    • 80. Petrov L, Mikhailitsyn FS, Kozyreva NP, Bolshakova A. The search for new antiparasitic agents. 16. A study of the anti-Fasciola activity of N-? (chloro- naphthyloxy) phenyl? benzamides. Med Parazitol (Mosk) 1996; 1: 25-26.

    • 81. Ping C, Hayes A. Acute toxicity and eyes irritancy. In: Principles and Methods of Toxicology, Third Edition, Edited by A. Wallace Hayes, Raven Press Ltd, New York. 1994.

    • 82. Poitou I, Baeza E, Boulard C. Humoral and cellular immune responses in rats during a primary infestation with Fasciola hepatica. Vet Parasitol. 1982; 45: 59-71.

    • 83. Robinson MW, Trudgett A, Hoey EM, Fairweather I. Triclabendazole-resistant Fasciola hepatica: beta-tubulin and response to in vitro treatment with triclabendazole. Parasitology 2002;124:325-38.

    • 84. Rossignol JF. Method for treatment of trematodes with pharmaceutical compositions of tizoxanide and nitazoxanide. US patent application number 5856348, 1999.

    • 85. Salki H, Taira N, Tomishita e Ischii T. Artificial inpection by transplantation of juvenile Fasciola worms into the abelomerial cavity of rats. Wippon-Swingaki- Zasshi. 1989; 51: 151-56.

    • 86. Sanchez-Andrade R, Paz-Silva A, Suarez JL, Panadero R, Pedreira J, Diez-Banos P, Morrondo P. Effect of fasciolicides on the antigenaemia in sheep naturally infected with Fasciola hepatica. Parasitol Res 2001;87:609-14.

    • 87. Shulman MD, Valentino D. Fasciola hepatica: effect of 4-amino-6-trichloroethenyl- 1, 3-benzenedisulphonamide on glycolysis in vitro. Expl Parasitol 1980; 49: 206-15.

    • 88. Sifontes S. DL50 de productos vinilfuránicos por vía intraperitoneal. Informe Técnico Centro de Bioactivos Químicos, Universidad Central de Las Villas. P. 1-15. 2000.

    • 89. Smith G, Grenfe BT. The influence o wuater temperature and ph on the survival of

    Fasciola hepática miracidium / 1984 ; 88: 97-104.

    • 90. Sobhon P, Anantavara S, Prasert T, Villanant V, Krailas D, Upathan ES, Wanichanon C. and Kusamran T. Fasciola gigantica: Studio of the tegument as a basis for the development of inmunodiagnosis and vaccine. Faculty of science, Mahidol university, Bangkok, Thailand. 1999; 29: 387-400.

    • 91. Spithill TW, Dalton JP. Progress in development of liver fluke vaccines. Parasitology Today 1998;14:224-28.

    • 92. Spithill TW, Morrison CA. Molecular vaccines for control of Fasciola hepatica

    Infection in ruminants. Immunology, Pathobiology and control of Fascioliasis. Ed. J.C. Boray. Rahway New Jersey: MSD AGVET. 1997: 29-35.

    • 93. Stammers BM. The effects of Nitroxynil on the survival, growth and morphology of Fasciola hepatica in sheep. Res Vet Sci 1975; 20: 174-79.

    • 94. Steward JS. Anthelmintic studies I.A. controlled critical enteromicidal test. Parasitol 1955; 45: 231-241.

    • 95. Sturdik E, Drobnica L, Balaz S. Interaccions of 2-furylethylenes with thiol enzimes.Coll Czech Chem Commum 1983a;48:327-35.

    • 96. Sturdik E, Drobnica L, Balaz S.Reactions of 2-furylethylenes with thiol in vivo. Oll Czech Commum 1983b;48:336-45.

    • 97. Terada M, Sano M, Ishii AI, Kino H, Fukushima S, Noro T. [Studies on chemotherapy of parasitic helminths (III). Effects of tuberostemonine from Stemona japonica on the motility of parasitic helminths and isolated host tissues].[Article in Japanese]. Nippon Yakurigaku Zasshi 1982; 79: 93-103.

    • 98. Thomas,J.MSkalski,J.F.Cline,MC.McShane,J.Csimposon,W.E.Miller,S.A.Peterson,C .A.Callahan and J.C.Greene, Characteruzation of Chimical Waste site Contamination and Determination of its Extent Using Bioassays. Environmental Toxicology and Chemistry 2000 5:487-501.

    • 99. Tliba O, Chauvin A, Le Vern Y, Boulard C, Sbille P. Evaluation of the hepatic NK cell response during the early phase of Fasciola hepatica infection in rats. Vet Res 2002b;33:327-32.

    • 100. Tliba O, Moire N, Le Vern Y, Boulard C, Chauvin A, Sibille P. Early hepatic immune response in rats infected with Fasciola hepat. Vet Res 2002a;33:261- 70.

    • 101. Tsocheva N, Krustev L, Polyakova O. Analisys of the changes of some quantitative parameters of the liver of Fasciola hepatica infected and diethylnitrosamim treated rats. Helminthologia 1992; 27: 261-68.

    • 102. Vercruysse J,HoldsworthP, Letonja T, Barth D, Conder G, Hamamoto K, OkanoK International harmonization of anthelmintic efficacy guidelines.2001;96:171-93.

    • 103. Wilson RA. Gland cells and secretions in the miracidium of Fasciola hepatica. Parasitol 1971; 63: 225-31.

    • 104. Wood IB, Amaral NK, Bairden K, Duncan J, Kassai T, Malone JB, et al. World Association for the advancement of Veterinary Parasitology ( W.A.A.P. ) second edition of guidelines for evaluating the efficacy of anthelmintics in ruminants (bovine, ovine, caprine ). Vet Parasitol 1995; 58: 181-213.

    • 105. Wolff,k, Eckert,J., Schnetter,G.& Luts, H.Efficacy of triclabendazole against. Fasciola hepatica in sheep and goats. Veterinary Parasitology 1983 13, 145- 50.

     

     

     

    Autor:

    Omelio Cepero Rodriguez

    Elsa Pimienta Rodriguez

    Jorge Orlay Serranio Torres

    Juan Jose Pulido .

    Curriculum Omelio Cepero Rodriguez

    Graduado en la carrera de Medicina Veterinaria. Defendió su doctorado en Leipzig, Alemania. 1988. Tiene publicado 184 trabajos en revistas Nacionales e Internacionales. Miembro titular de la Sociedad de Epizootiologia. Desde el año 1992, dirige el tema de Investigación: "Impacto de los desastres en la salud y producción animal y vegetal en la Facultad de Ciencias Agropecuarias de la Universidad Central de las Villas. Autor de veinte libros. Profesor Titular.

    Partes: 1, 2
     Página anterior Volver al principio del trabajoPágina siguiente